Phase I/II trial of Intracerebral Transplantation of Autologous Bone Marrow Stromal Cells Combined with Recombinant Peptide Scaffold for Patients with Chronic Intracerebral Hemorrhage

Kawabori Masahito0 个研究点目标入组 8 人开始时间: 2023年12月6日最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•1. Age between 20 and 70 years
•2. Clinical diagnosis of intracerebral hemorrhage 12 month or more from onset
•3. Hemorrhagic location of unilateral basal ganglia or thalamus
•4. Moderate to severe neurological symptoms; mRS 3 or 4, and Brunnstrom stage III or IV
•5. No significant neurological impairment before hemorrhage (Pre-hemorrhagic mRS of 0 or 1)
•6. Subjects who can give informed consent by its self

•1. Severe microbleeds
•2. Hemorrhagic cavity less than 2 mL
•3. The hemorrhage is due to arteriovenous malformation, cerebral aneurysm, and Moyamoya disease
•4. Subject showing obvious communication between the hemorrhagic cavity and lateral ventricle on MRI
•5. Subject showing severe lower extremity contracture (Maximum knee extension less than -15 degrees, Maximum ankle flexion less than 0 degree)
•6. Subject's body weight less than 45 kg for male and 40kg for female

发起方

Kawabori Masahito